Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving EyePoint Pharmaceuticals (EYPT)GlobeNewsWire · 2 days ago
EyePoint (NASDAQ: EYPT) cuts 53% of staff after DURAVYU wet AMD missDefense World · 3 days ago
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint PharmaceuticalsGuruFocus · 4 days ago
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint PharmaceuticalsPRNewsWire · 4 days ago
EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT)PRNewsWire · 5 days ago
EyePoint Slashing Workforce, Halting Clinical Trials to Pivot FocusBenzinga · 5 days agoEyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$1.01 | -$1.09 | Miss |
| May 6, 2026 | -$0.79 | -$0.99 | Miss |
| Mar 4, 2026 | -$0.78 | -$0.81 | Miss |
| Nov 5, 2025 | -$0.77 | -$0.85 | Miss |
| Aug 6, 2025 | -$0.67 | -$0.85 | Miss |
| May 7, 2025 | -$0.65 | -$0.65 | Beat |